Oculis (NASDAQ:OCS) Shares Gap Up – Still a Buy?

Oculis Holding AG (NASDAQ:OCS)’s share price gapped up prior to trading on Thursday . The stock had previously closed at $17.76, but opened at $18.13. Oculis shares last traded at $17.80, with a volume of 13,174 shares changing hands.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. HC Wainwright raised their target price on Oculis from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Thursday, April 17th. Robert W. Baird raised their target price on Oculis from $37.00 to $41.00 and gave the stock an “outperform” rating in a report on Thursday, March 13th. Finally, Chardan Capital raised their target price on Oculis from $28.00 to $33.00 and gave the stock a “buy” rating in a report on Friday, May 9th.

Oculis Trading Down 2.5%

The business has a fifty day simple moving average of $17.94 and a 200-day simple moving average of $18.40. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02. The firm has a market cap of $779.37 million, a price-to-earnings ratio of -9.25 and a beta of 0.27.

Oculis (NASDAQ:OCS) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.26). The company had revenue of $0.32 million during the quarter, compared to analyst estimates of $0.22 million. Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%. As a group, equities analysts forecast that Oculis Holding AG will post -2.09 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Oculis

Hedge funds have recently added to or reduced their stakes in the company. Bellevue Group AG purchased a new position in shares of Oculis during the fourth quarter valued at approximately $170,000. XTX Topco Ltd purchased a new position in shares of Oculis during the fourth quarter valued at approximately $225,000. Kestra Private Wealth Services LLC purchased a new position in shares of Oculis during the first quarter valued at approximately $234,000. Geode Capital Management LLC boosted its position in shares of Oculis by 12.0% during the fourth quarter. Geode Capital Management LLC now owns 16,744 shares of the company’s stock valued at $284,000 after buying an additional 1,800 shares during the last quarter. Finally, Citadel Advisors LLC purchased a new position in shares of Oculis during the fourth quarter valued at approximately $389,000. Institutional investors and hedge funds own 22.30% of the company’s stock.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.